Ventripoint Diagnostics Enters Advisory Agreement with Fournel Advisory to Accelerate AI Heart-Scanning Technology Commercialization

Toronto, Ontario — June 17, 2025 — NewsWall — Ventripoint Diagnostics Ltd. (TSXV:VPT; OTC:VPTDF) has entered into an advisory agreement with Fournel Advisory to bolster the commercialization of its AI-powered heart-scanning technology. The one-year agreement includes financial advisory, business development, and M&A services.

Under the agreement, Ventripoint will provide Fournel with a cash fee and an option to purchase 265,000 common shares at $0.11, the market price on June 11, 2025, pending TSX Venture Exchange approval.

Fournel Advisory, a Paris-based consulting firm, specializes in M&A advisory, fundraising, and special situations for Small and Mid-Cap markets, with a focus on Healthcare and Life Sciences. Founded by Pierre-Jean Esmieu Fournel, the firm has completed over 50 transactions and currently manages around 30 active mandates.

Ventripoint President and CEO Hugh MacNaught stated that Fournel Advisory's experience in the Healthcare sector and extensive network will be invaluable in accelerating Ventripoint’s growth. Pierre-Jean Esmieu Fournel added that they are excited to partner with Ventripoint and leverage their global network to support Ventripoint’s growth and long-term success.

Ventripoint's VMS+™ platform utilizes AI to enhance echocardiography, providing an affordable alternative to MRI scans. The company is now positioned to expand its market presence following recent regulatory approvals.

Contact: Hugh MacNaught, hmacnaught@ventripoint.com, (604) 671-4201

Source: Ventripoint Diagnostics Ltd.